Effect of Iron-fortified Pea Powder on Exercise Performance
Overview
Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study assesses the impact of an pea protein supplement with high iron bio-availability on iron status and exercise performance.
Full Title of Study: “Effect of Low-phytate Pea Powder With High Iron Bioavailability on Iron Status of Female Runners”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Study Primary Completion Date: June 30, 2022
Detailed Description
Female endurance athletes are susceptible to iron deficiency due to poor iron intake from diets or possibly because of destruction of red blood cells during foot-strike hemolysis. This study will evaluate the impact of 8-weeks of iron supplementation through consumption of a pea-protein power that has high iron bio-availability due to low phytate levels. This will be compared to consumption of regular iron protein powder and maltodextrin placebo by randomizing participants to three groups. Participants will be assessed at baseline and after 8 weeks of supplementation for exercise performance (maximal aerobic capacity and a 5 km time trial running test), blood levels of ferritin and hemoglobin, and body composition (fat mass and lean tissue mass).
Interventions
- Dietary Supplement: Low phytate pea powder
- Exercise performance with low phytate pea powder
- Dietary Supplement: Regular pea powder
- Exercise performance with regular pea powder
- Dietary Supplement: Placebo (maltodextrin)
- Exercise performance with placebo (maltodextrin)
Arms, Groups and Cohorts
- Experimental: Pea power with high iron bio-availability
- Pea powder with low phytate levels to increase iron bio-availability (7mg iron per day)
- Active Comparator: Pea powder
- Pea powder with normal phytate levels (7mg iron per day)
- Placebo Comparator: Placebo
- Placebo (maltodextrin) powder (0g iron per day)
Clinical Trial Outcome Measures
Primary Measures
- Change from baseline in ferritin levels
- Time Frame: Up to 8 weeks
- blood ferritin levels
Secondary Measures
- Change from baseline in maximal aerobic capacity
- Time Frame: Up to 8 weeks
- Maximal aerobic capacity (mL/kg/min) measured on a treadmill
- Change from baseline in exercise time trial performance
- Time Frame: Up to 8 weeks
- Time (minutes) to complete 5 km running on a treadmill
- Change from baseline in hemoglobin levels
- Time Frame: Up to 8 weeks
- Blood hemoglobin concentration
- Change from baseline in lean tissue mass
- Time Frame: Up to 8 weeks
- Lean tissue mass (kg) measured with dual energy X-ray absorptiometry
- Change from baseline in fat mass
- Time Frame: Up to 8 weeks
- Fat mass (kg) measured with dual energy X-ray absorptiometry
Participating in This Clinical Trial
Inclusion Criteria
- Female – Regularly participate in aerobic endurance training Exclusion Criteria:
- Any contra-indications to exercise testing as determined with the "Get Active Questionnaire"
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: 50 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- University of Saskatchewan
- Provider of Information About this Clinical Study
- Principal Investigator: Phil Chilibeck, Professor – University of Saskatchewan
- Overall Official(s)
- Philip Chilibeck, Ph.D., Principal Investigator, University of Saskatchewan
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.